Arvinas (NASDAQ:ARVN) Downgraded to Neutral Rating by The Goldman Sachs Group

Arvinas (NASDAQ:ARVN - Get Free Report) was downgraded by equities research analysts at The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a research report issued on Thursday,Briefing.com Automated Import reports. They presently have a $15.00 price target on the stock, down from their prior price target of $70.00. The Goldman Sachs Group's price objective would indicate a potential upside of 66.11% from the stock's previous close.

A number of other equities analysts also recently weighed in on ARVN. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They set an "overweight" rating and a $55.00 target price on the stock. Wedbush downgraded shares of Arvinas from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $57.00 to $12.00 in a report on Wednesday. Wells Fargo & Company set a $26.00 target price on shares of Arvinas and gave the stock an "overweight" rating in a report on Wednesday. Finally, Citigroup lowered their target price on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating on the stock in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $41.07.

Remove Ads

Arvinas Price Performance

Arvinas stock opened at $9.03 on Thursday. The company's 50 day simple moving average is $17.97 and its 200 day simple moving average is $22.20. The firm has a market capitalization of $621.01 million, a price-to-earnings ratio of -3.26 and a beta of 1.95. Arvinas has a fifty-two week low of $7.91 and a fifty-two week high of $46.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm earned ($2.53) EPS. As a group, analysts predict that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares of the company's stock, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,572 shares of company stock valued at $695,030 over the last quarter. 5.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. acquired a new stake in Arvinas during the 4th quarter valued at approximately $28,000. KBC Group NV increased its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Quantbot Technologies LP increased its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Arvinas during the 4th quarter valued at approximately $171,000. Finally, Tema Etfs LLC acquired a new stake in Arvinas during the 4th quarter valued at approximately $227,000. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.